AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31305326 — intervention group
Group type: COMPARATOR
Intervention: Conventional milk
Number of subjects: 0
Study 28918548 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 62
Study 28918548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 26745028 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with a history of GDM and BMI <30 kg/m²
Number of subjects: 269
Study 26745028 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 269
Study 24647726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 286
Study 24647726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral relapse prevention (RP)
Number of subjects: 286
Study 24647726 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 286
Study 22552027 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine polyphenols
Number of subjects: 10
Study 22552027 — intervention group
Group type: COMPARATOR
Intervention: De-alcoholized red wine
Number of subjects: 10
Study 22552027 — intervention group
Group type: COMPARATOR
Intervention: Gin
Number of subjects: 10
Study 20545561 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based olive oil diet (PBOO; >= 3 tablespoons of olive oil/day)
Number of subjects: 44
Study 20545561 — intervention group
Group type: COMPARATOR
Intervention: Standard lower-fat diet (NCI diet; total fat > 15% and < 30%)
Number of subjects: 44
Study 20545561 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based olive oil diet (PBOO)
Number of subjects: 44
Study 17613157 — intervention group
Group type: EXPERIMENTAL
Intervention: Resourcefulness Training (RT)
Number of subjects: 176
Study 17613157 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance Training (AT)
Number of subjects: 176
Study 17613157 — intervention group
Group type: COMPARATOR
Intervention: Diversional Activities (DA)
Number of subjects: 176
Study 16040785 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 185
Study 16040785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 12070197 — intervention group
Group type: EXPERIMENTAL
Intervention: REM sleep
Number of subjects: 26
Study 12070197 — intervention group
Group type: EXPERIMENTAL
Intervention: NREM sleep
Number of subjects: 26
Study 10191171 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD fMRI
Number of subjects: 0
Study 10191171 — intervention group
Group type: COMPARATOR
Intervention: PET
Number of subjects: 0
Study 8649942 — intervention group
Group type: COMPARATOR
Intervention: Hypovolemic state (before therapy)
Number of subjects: 10
Study 8649942 — intervention group
Group type: COMPARATOR
Intervention: Normovolemic state (after plasma expander)
Number of subjects: 10
Study 8649942 — intervention group
Group type: COMPARATOR
Intervention: Two-week anticoagulant treatment (dicumarol therapy)
Number of subjects: 10
Study 2085966 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu220C
Number of subjects: 0
Study 2085966 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload 250
Number of subjects: 0
Study 2085966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova T
Number of subjects: 0
Study 2085966 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu380A
Number of subjects: 0
Study 37868 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg)
Number of subjects: 0
Study 37868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31450977 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for sex classification
Number of subjects: 275056
Study 31450977 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for age estimation
Number of subjects: 275056
Study 31450977 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for age estimation in patients with multiple ECGs
Number of subjects: 275056
Study 31450977 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for correlation of predicted and chronological age
Number of subjects: 275056
Study 29029185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 29029185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus MTX
Number of subjects: 0
Study 27652911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 215
Study 27652911 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexmedetomidine)
Number of subjects: 215
Study 24873720 — intervention group
Group type: EXPERIMENTAL
Intervention: Davunetide (30 mg twice daily, intranasally)
Number of subjects: 313
Study 24873720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 23037494 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) dissection alone
Number of subjects: 0
Study 23037494 — intervention group
Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 0
Study 18468856 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17312305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 2471
Study 17312305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2471
Study 15207404 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (66 patients) with additional home care attendance provided by a lay-working person who attended a specialized course.
Number of subjects: 127
Study 15207404 — intervention group
Group type: COMPARATOR
Intervention: Control group (61 patients) with usual home care program of assistance.
Number of subjects: 127
Study 10714728 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL (25 mg once per day for NYHA class II or 12.5 mg once per day for NYHA class III or IV, titrated up to 200 mg once per day)
Number of subjects: 3991
Study 10714728 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 3991
Study 9187478 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (CZP)
Number of subjects: 40
Study 9187478 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 40
Study 9187478 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 40
Study 23087948 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (dosage not specified, but mentions up to 10 g/day and 5 g/day as safe)
Number of subjects: 0
Study 23087948 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (megadose therapy)
Number of subjects: 0
Study 23087948 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (up to 5 g/day)
Number of subjects: 0
Study 23087948 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 0
Study 3816292 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg cimetropium bromide
Number of subjects: 40
Study 3816292 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cimetropium bromide
Number of subjects: 40
Study 31992403 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 31
Study 31992403 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 31
Study 31992403 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies (MAD and CPAP)
Number of subjects: 31
Study 31397122 — intervention group
Group type: EXPERIMENTAL
Intervention: Thunder-fire moxibustion combined with external application of Shuangbai powder
Number of subjects: 70
Study 31397122 — intervention group
Group type: COMPARATOR
Intervention: Simple thunder-fire moxibustion
Number of subjects: 70
Study 28367845 — intervention group
Group type: EXPERIMENTAL
Intervention: evolocumab + standard of care (SOC)
Number of subjects: 0
Study 28367845 — intervention group
Group type: COMPARATOR
Intervention: standard of care (SOC) alone
Number of subjects: 0
Study 25246305 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexmedetomidine 2 µg/kg (Group D1)
Number of subjects: 160
Study 25246305 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexmedetomidine 3 µg/kg (Group D2)
Number of subjects: 160
Study 25246305 — intervention group
Group type: COMPARATOR
Intervention: Oral chloral hydrate 50 mg/kg (Group C1)
Number of subjects: 160
Study 25246305 — intervention group
Group type: COMPARATOR
Intervention: Oral chloral hydrate 100 mg/kg (Group C2)
Number of subjects: 160
Study 23537071 — intervention group
Group type: EXPERIMENTAL
Intervention: VV genotype in dysglycemic patients
Number of subjects: 611
Study 21697250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (4,000-40,000 IU/d) plus calcium (1200 mg/d), followed by equilibration to 10,000 IU/d
Number of subjects: 49
Study 21697250 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 49
Study 18295439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral protection group (with filter)
Number of subjects: 35
Study 18295439 — intervention group
Group type: COMPARATOR
Intervention: No cerebral protection group (without filter)
Number of subjects: 35
Study 17302076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine plus clonidine, continuous infusion 10 mL x h(‐1)
Number of subjects: 105
Study 17302076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine plus clonidine, continuous infusion 10 mL x h(‐1)
Number of subjects: 105
Study 17302076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine plus clonidine, PCA system 5 mL every 30 minutes
Number of subjects: 105
Study 17302076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine plus clonidine, PCA system 5 mL every 30 minutes
Number of subjects: 105
Study 17302076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine plus clonidine, continuous infusion 5 mL h x (‐1) plus PCA 2.5 mL every 30 minutes
Number of subjects: 105
Study 17302076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine plus clonidine, continuous infusion 5 mL h x (‐1) plus PCA 2.5 mL every 30 minutes
Number of subjects: 105
Study 12699211 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly physician visits
Number of subjects: 87
Study 12699211 — intervention group
Group type: COMPARATOR
Intervention: Semi-annual physician visits
Number of subjects: 87
Study 12699211 — intervention group
Group type: COMPARATOR
Intervention: Semiannual physician visits and monthly nurse phone calls
Number of subjects: 87
Study 10849265 — intervention group
Group type: EXPERIMENTAL
Intervention: kurorinone 400 mg daily for 3 months
Number of subjects: 94
Study 10849265 — intervention group
Group type: COMPARATOR
Intervention: interferon-alpha (IFN-alpha) 3 million units daily for 1 month, every other day for 2 months for 3 months
Number of subjects: 94
Study 9213980 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide-preventive intervention
Number of subjects: 13
Study 9213980 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study 8256707 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 224
Study 8256707 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic implantable cardioverter-defibrillator
Number of subjects: 224
Study 8256707 — intervention group
Group type: COMPARATOR
Intervention: Control group (other antiarrhythmic drug therapy)
Number of subjects: 224
Study 3899082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.2 mg)
Number of subjects: 25
Study 3899082 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.2 mg)
Number of subjects: 25
Study 3899082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30093216 — intervention group
Group type: EXPERIMENTAL
Intervention: Double acquisition protocol (group 1, 50 patients)
Number of subjects: 100
Study 30093216 — intervention group
Group type: COMPARATOR
Intervention: Single acquisition protocol (group 2, 50 patients)
Number of subjects: 100
Study 30093216 — intervention group
Group type: EXPERIMENTAL
Intervention: Double acquisition protocol (group 1)
Number of subjects: 100
Study 30093216 — intervention group
Group type: COMPARATOR
Intervention: Single acquisition protocol (group 2)
Number of subjects: 100
Study 28612668 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 20 mg as a single dose
Number of subjects: 40
Study 28612668 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics only (Control)
Number of subjects: 40
Study 27481077 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 µg/Fluticasone 500 µg combination (SF Group)
Number of subjects: 44
Study 27481077 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 µg (T Group)
Number of subjects: 44
Study 27481077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SF Group and T Group)
Number of subjects: 44
Study 25274710 — intervention group
Group type: COMPARATOR
Intervention: Financial Incentive
Number of subjects: 92
Study 25274710 — intervention group
Group type: COMPARATOR
Intervention: Peer Network
Number of subjects: 92
Study 25274710 — intervention group
Group type: COMPARATOR
Intervention: Combined
Number of subjects: 92
Study 23518801 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion (PE)
Number of subjects: 34
Study 23518801 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 34
Study 20020282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek seed extract
Number of subjects: 39
Study 20020282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 18996241 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy Assistant WREX
Number of subjects: 10
Study 16478747 — intervention group
Group type: EXPERIMENTAL
Intervention: MDM2-SNP309 (T/G or G/G genotype)
Number of subjects: 153
Study 16478747 — intervention group
Group type: COMPARATOR
Intervention: T/T genotype
Number of subjects: 153
Study 16478747 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between T/T genotype and MDM2-SNP309 (T/G or G/G genotype)
Number of subjects: 153
Study 14639794 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy soup consumers
Number of subjects: 4988
Study 14639794 — intervention group
Group type: COMPARATOR
Intervention: Regular soup consumers
Number of subjects: 4988
Study 14639794 — intervention group
Group type: COMPARATOR
Intervention: Occasional/non-soup consumers
Number of subjects: 4988
Study 11143786 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 11143786 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 7802862 — intervention group
Group type: EXPERIMENTAL
Intervention: Clivarin 20 anti F Xa U/kg BW
Number of subjects: 10
Study 7802862 — intervention group
Group type: EXPERIMENTAL
Intervention: Clivarin 40 anti F Xa U/kg BW
Number of subjects: 10
Study 7802862 — intervention group
Group type: EXPERIMENTAL
Intervention: Clivarin 60 anti F Xa U/kg BW
Number of subjects: 10
Study 7802862 — intervention group
Group type: EXPERIMENTAL
Intervention: Clivarin 80 anti F Xa U/kg BW
Number of subjects: 10
Study 3063045 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg i.v. and a supplementary 0.025 mg/kg every second min until sleep or dysarthria, followed by paracervical blockade with 1% mepivacaine 10 ml on each side of the portio
Number of subjects: 60
Study 3063045 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2.5 micrograms/kg and thiopentone 2 mg/kg i.v. with supplementary thiopentone 50 mg every 15 s until loss of the eyelid reflex, maintained with nitrous oxide in oxygen 2/1 and supplementary thiopentone 50 mg as required
Number of subjects: 60
Study 31470005 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous vedolizumab 108 mg every 2 weeks
Number of subjects: 216
Study 31470005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vedolizumab 300 mg every 8 weeks
Number of subjects: 216
Study 31470005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 31470005 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous vedolizumab
Number of subjects: 216
Study 29879942 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE SOAP©
Number of subjects: 287
Study 29879942 — intervention group
Group type: COMPARATOR
Intervention: Control soap
Number of subjects: 287
Study 28479255 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel applied every night before surgery
Number of subjects: 65
Study 28479255 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel applied once before surgery
Number of subjects: 65
Study 28479255 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel
Number of subjects: 65
Study 28479255 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel with >1 application
Number of subjects: 65
Study 26431213 — intervention group
Group type: EXPERIMENTAL
Intervention: In-school asthma class
Number of subjects: 0
Study 26431213 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma day camp
Number of subjects: 0
Study 26431213 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 0
Study 22653374 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (daily education about sitting correctly and video demonstrations of exercises)
Number of subjects: 100
Study 22653374 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 100
Study 21212755 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and antioxidants (vitamins E+C)
Number of subjects: 0
Study 21212755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19720877 — intervention group
Group type: EXPERIMENTAL
Intervention: PH-797804 (N-phenyl pyridinone p38 MAP kinase inhibitor)
Number of subjects: 0
Study 17251533 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b treatment
Number of subjects: 462
Study 17251533 — intervention group
Group type: COMPARATOR
Intervention: Presence of anti‐MOG and anti‐MBP antibodies
Number of subjects: 462
Study 15482993 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 400 mg ml(‐1) (98 ml, injection rate 5 ml s(‐1))
Number of subjects: 50
Study 15482993 — intervention group
Group type: COMPARATOR
Intervention: Iomeprol 300 mg ml(‐1) (130 ml, injection rate 5 ml s(‐1))
Number of subjects: 50
Study 11743591 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 0
Study 11743591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9757156 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of 15 ng/kg body weight/min urodilatin
Number of subjects: 20
Study 9757156 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of 22.5 ng/kg body weight/min urodilatin
Number of subjects: 20
Study 9757156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8573808 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic CPB (34 degrees C perfusate temperature)
Number of subjects: 16
Study 8573808 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic CPB (28 degrees C perfusate temperature)
Number of subjects: 16
Study 8573808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Normothermic and Hypothermic)
Number of subjects: 16
Study 2114782 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate, prehospital treatment initiation with rt-PA (recombinant tissue-type plasminogen activator)
Number of subjects: 190
Study 2114782 — intervention group
Group type: COMPARATOR
Intervention: Delayed, in-hospital treatment initiation with rt-PA
Number of subjects: 190
Study 152663 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation and manipulation
Number of subjects: 94
Study 152663 — intervention group
Group type: COMPARATOR
Intervention: Placebo physiotherapy
Number of subjects: 94
Study 31823163 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing from day 3 to day 10 of hospitalization
Number of subjects: 91
Study 31823163 — intervention group
Group type: COMPARATOR
Intervention: Control group (no expressive writing)
Number of subjects: 91
Study 31823163 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 91
Study 29283786 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate 0.5% (Group LE)
Number of subjects: 150
Study 29283786 — intervention group
Group type: COMPARATOR
Intervention: Topical Dexamethasone 1% (Group DEX)
Number of subjects: 150
Study 28295931 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 192
Study 26622431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 90Sr-90Y therapy combined with 0.5% timolol maleate solution
Number of subjects: 72
Study 26622431 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline with identical dose of 90Sr-90Y
Number of subjects: 72
Study 23537330 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant (SCT) patients
Number of subjects: 627
Study 23537330 — intervention group
Group type: COMPARATOR
Intervention: Medical (MED) or Radiation (RAD) oncology patients
Number of subjects: 627
Study 21543962 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 57
Study 19530911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 100
Study 19530911 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 100
Study 16923826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft
Number of subjects: 64
Study 16923826 — intervention group
Group type: COMPARATOR
Intervention: Patellar tendon autograft
Number of subjects: 64
Study 15327406 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cystatin C
Number of subjects: 85
Study 11220420 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium for intubation and maintenance (Group RR)
Number of subjects: 78
Study 11220420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium for intubation and rocuronium for maintenance (Group PR)
Number of subjects: 78